Advertising disclosure: This page contains affiliate links. As an Amazon Associate, and through other partner programs, we may earn a commission from qualifying purchases — at no extra cost to you. Learn more.
Vitamin K2 is arguably the most underappreciated fat-soluble vitamin in modern nutrition — an essential nutrient that directs calcium to bones and teeth while actively preventing its accumulation in arteries, yet one that up to 97% of Western adults are deficient in. Unlike vitamin K1 (which governs blood clotting), K2 operates primarily through two proteins — osteocalcin and matrix Gla protein — that control where calcium goes in the body. Understanding the critical difference between MK-4 and MK-7 forms determines whether your supplement actually works. This guide covers everything you need to know about vitamin K2 in 2026, including the clinical evidence, precise dosing, and how to combine it with vitamin D3 for maximum benefit.
Get our Supplement Dosing Guide — free.
The exact dosages from 200+ peer-reviewed studies, compiled into one reference PDF. No fluff, no upsell.
🔒 No spam. Unsubscribe anytime. We send 1-2 emails/month max.
- Vitamin K2 MK-7 (180 mcg/day for 3 years) significantly increased bone mineral density and reduced vertebral fracture risk in postmenopausal women in the MsOS study (Knapen et al., 2013, Osteoporosis International).
- Matrix Gla protein (MGP) activated by K2 is the most potent known inhibitor of vascular calcification; Rotterdam Study data (Geleijnse et al., 2004, Journal of Nutrition) showed 57% lower risk of aortic calcification in the highest K2 (not K1) quartile.
- MK-7 has a half-life of 72 hours vs. MK-4’s 1–2 hours, making MK-7 more suitable for once-daily supplementation and producing consistently higher carboxylation of K2-dependent proteins.
- Vitamin K2 does not cause blood clotting at supplemental doses and can be safely taken by most individuals on warfarin with physician supervision and dose monitoring.
What Is Vitamin K2? The K Vitamin Family Explained
The vitamin K family comprises two naturally occurring vitamers with distinct biological roles. Vitamin K1 (phylloquinone) is found primarily in leafy green vegetables and functions mainly in the liver, where it activates clotting factors II, VII, IX, and X — the classic “K” for koagulation. Vitamin K2 (menaquinone) is a family of related compounds (MK-4 through MK-13, distinguished by their side chain length) produced by bacteria and found in fermented foods and animal products. K2 is distributed extrahepatic — it reaches bone, arteries, kidney, and other tissues where K1 is scarce. The two vitamers activate overlapping but distinct sets of vitamin K-dependent proteins (VKDPs). There are at least 17 VKDPs identified in humans; the most clinically relevant for K2 are osteocalcin (bone matrix protein) and matrix Gla protein (MGP — arterial calcification inhibitor), both of which are primarily activated by K2. A Western diet rich in leafy greens provides adequate K1 for clotting but insufficient K2 for optimal extrahepatic VKDP carboxylation — explaining why blood clotting tests (PT/INR) can be normal while K2-dependent tissues are functionally deficient. For the critical D3+K2 synergy, see our dedicated vitamin D3 vs D3+K2 article.
MK-4 vs. MK-7: The Critical Difference
The two forms of K2 available in supplements — MK-4 and MK-7 — differ fundamentally in their pharmacokinetics, which determines their practical utility at different doses.
MK-4 (Menatetrenone)
MK-4 has a short biological half-life of 1–2 hours. This means plasma levels peak sharply after ingestion and fall rapidly, providing only transient activation of K2-dependent proteins. To maintain adequate tissue saturation, MK-4 must be dosed multiple times daily. The doses used in Japanese clinical trials for osteoporosis (where MK-4 is an approved pharmaceutical drug called menatetrenone/Glakay) are 45,000 mcg/day (45 mg/day) — 45–100x higher than typical supplement doses of 100–500 mcg/day. At these pharmacological doses, MK-4 demonstrates significant reductions in vertebral fracture rates (65% reduction in one RCT by Sato et al., 1998). However, the very high doses required make MK-4 impractical for typical supplementation compared to MK-7. MK-4 is found naturally in animal products (particularly chicken, butter, and gouda cheese) but at low concentrations.
MK-7 (Menaquinone-7)
MK-7 has a dramatically longer half-life of 72 hours (3 days), resulting in stable, sustained plasma concentrations from a single daily dose. MK-7 is more effective than MK-4 at activating osteocalcin and MGP at the doses practical for supplementation (90–360 mcg/day). A landmark randomized controlled trial by Knapen et al. (2013, Osteoporosis International) administered 180 mcg/day MK-7 (from natto-derived MenaQ7) to postmenopausal women for 3 years and demonstrated significant increases in bone mineral content (BMC) and BMD at the lumbar spine and femoral neck vs. placebo, along with significant reductions in height loss (a proxy for vertebral compression fractures). MK-7 is found naturally in natto (fermented soybeans) at exceptionally high concentrations (900–1,100 mcg per 100g) and to a lesser extent in other fermented foods and cheese. For supplementation, all-trans MK-7 (the biologically active isomer, as opposed to cis-MK-7) is the only form with clinical evidence — check that your supplement specifies “all-trans MK-7” or uses the branded MenaQ7 ingredient.
Bone Health: The Evidence
Vitamin K2 activates osteocalcin — the protein secreted by osteoblasts that binds calcium and incorporates it into the hydroxyapatite crystal matrix of bone. Without adequate K2, osteocalcin remains undercarboxylated (inactive) and circulates without performing its calcium-binding function, leaving bone matrix poorly mineralized despite adequate calcium intake. This explains an important clinical paradox: populations with high calcium intake but low K2 intake (such as many Western populations) can simultaneously have osteoporosis and vascular calcification — calcium is present but not being directed appropriately. The Rotterdam Study (n=4,807) found that dietary K2 intake — but not K1 — was inversely associated with aortic calcification, all-cause mortality, and cardiovascular mortality over 10-year follow-up. Multiple subsequent RCTs have confirmed bone-specific benefits of MK-7 supplementation, including a 2019 trial by van Ballegooijen et al. confirming that MK-7 significantly improved carboxylation of osteocalcin within 4 weeks at 180 mcg/day. For comprehensive bone health supplementation strategy including calcium, D3, magnesium, and K2, the D3+K2 combination is the essential starting point — see our vitamin D3 vs D3+K2 guide.
Cardiovascular Protection: Preventing Arterial Calcification
Matrix Gla protein (MGP) is the most potent known inhibitor of vascular and soft-tissue calcification. MGP requires vitamin K2 for carboxylation (activation); uncarboxylated MGP (dp-ucMGP) is inactive and associated with accelerated arterial calcification, stiffness, and cardiovascular events. In Western populations, 97% of subjects have detectable uncarboxylated MGP in plasma — suggesting widespread functional K2 insufficiency in arterial tissue. The clinical significance is substantial: a meta-analysis by Dalmeijer et al. (2012) found that higher dietary menaquinone (K2) intake was associated with significantly lower risk of coronary heart disease, all-cause mortality, and severe aortic calcification. An important intervention trial (VitaK-CAC study, Vossen et al., 2015) found that MK-7 supplementation (180 mcg/day for 2 years) stabilized coronary artery calcium scores in patients with existing calcification, while placebo subjects showed progressive calcification — a clinically meaningful finding. The calcium-vitamin D3-K2 axis represents the most evidence-supported nutritional strategy for arterial health: vitamin D3 increases calcium absorption, K2 activates MGP to prevent that calcium from depositing in arteries. Taking vitamin D3 without K2 may theoretically worsen arterial calcification risk by increasing circulating calcium without adequate MGP activation.
Additional Benefits: Insulin Sensitivity, Testosterone, and Cancer
Osteocalcin — the K2-dependent bone protein — has a surprising second function: it acts as a hormone that stimulates insulin secretion from pancreatic beta cells and improves peripheral insulin sensitivity. Animal data is compelling (osteocalcin-knockout mice develop glucose intolerance and obesity), and human observational studies consistently link higher carboxylated osteocalcin with better glycemic parameters and lower type 2 diabetes risk. In men, carboxylated osteocalcin stimulates testosterone production by Leydig cells — an intriguing mechanism for K2’s reported benefits on male hormonal health, though RCT evidence in humans remains limited. For cancer, population studies have repeatedly found inverse associations between K2 intake and prostate cancer risk specifically: a large prospective analysis (European Prospective Investigation into Cancer and Nutrition, Nimptsch et al., 2009) found that high MK intake was associated with 35% lower prostate cancer risk (HR 0.65, 95% CI 0.49–0.86), with no association found for K1. The mechanism involves K2-mediated induction of apoptosis in cancer cell lines, including prostate, lung, and leukemia cells — active research areas.
Dosage & Timing
| Goal | Form | Dose | Timing | Notes |
|---|---|---|---|---|
| Bone health / osteoporosis prevention | MK-7 (all-trans) | 180–360 mcg/day | With the fattiest meal (fat-soluble) | 180 mcg is the RCT-validated dose; 360 mcg for therapeutic bone support |
| Cardiovascular / arterial calcification | MK-7 | 180 mcg/day | With D3 and a fat-containing meal | Combine with D3 (2,000–5,000 IU); allow 6–12 months to see MGP carboxylation improvement |
| D3+K2 daily stack (general health) | MK-7 | 90–180 mcg with 2,000–5,000 IU D3 | With lunch or dinner | The most practical all-purpose combination; look for combined capsule products |
| Osteoporosis treatment (pharmacological) | MK-4 | 45,000 mcg/day (45 mg) | Three divided doses with meals | Requires physician supervision; approved drug in Japan; not standard OTC use |
| General K2 sufficiency maintenance | MK-7 | 90–120 mcg/day | With any fat-containing meal | Adequate for most adults with reasonable dietary K2 from cheese and fermented foods |
Dietary Sources of Vitamin K2
Natto (fermented soybeans) is by far the richest dietary source of MK-7, containing 900–1,100 mcg per 100g serving — enough to supply several days’ worth of K2 in a single serving. Unfortunately, natto’s strong flavor and sticky texture make it unpalatable for most Western consumers. Other meaningful K2 sources: gouda and edam cheese (MK-8 and MK-9, medium-chain menaquinones) at 75–80 mcg/100g; brie and camembert (49–68 mcg/100g); egg yolks (primarily MK-4, ~32 mcg/100g); butter from grass-fed cows (15 mcg/100g); and chicken liver (MK-4, 14 mcg/100g). The critical insight: most K2 in cheese comes from bacterial fermentation, not the animal itself — unpasteurized or traditionally fermented cheeses tend to have higher K2 content. A typical Western diet provides approximately 10–25 mcg/day K2 — far below the 45–360 mcg associated with clinical benefits, explaining why supplementation is necessary for most adults not eating natto regularly.
Side Effects & Safety
- Extremely well tolerated: Vitamin K2 has no established tolerable upper limit; no adverse effects have been reported at doses up to 360 mcg/day MK-7 or even higher in clinical trials spanning 3 years.
- Warfarin / anticoagulant interaction: K2 can reduce the efficacy of warfarin (a vitamin K antagonist) — but the interaction is manageable with dose monitoring. Do not make sudden large changes in K2 intake while on warfarin; discuss with your physician and monitor INR. Newer anticoagulants (rivaroxaban, apixaban) do not interact with vitamin K.
- Cis-MK-7 contamination: Some MK-7 supplements contain significant amounts of biologically inactive cis-MK-7 isomers; ensure products specify “all-trans MK-7” or use branded MenaQ7 to guarantee the active form.
- Fat-soluble absorption requirement: K2 is fat-soluble; taking it with a fat-free meal significantly reduces absorption. Always take with a meal containing at least 10–15g of dietary fat.
- Pregnancy: Vitamin K2 is considered safe in pregnancy at dietary and supplemental doses up to 180 mcg/day; it is essential for fetal bone development. Higher doses should be discussed with an OB/GYN.
Our Top Picks
We’ve reviewed the best vitamin K2 supplements on Amazon, evaluating form (all-trans MK-7 only), dose, third-party testing, and synergistic formulation with D3. Our top recommendation for most users is a combined D3+K2 capsule for convenience and synergistic absorption. For standalone K2, MenaQ7-branded supplements (the form used in published RCTs) are the evidence-backed choice. See our detailed vitamin D3 vs D3+K2 guide for full product rankings and the D3 dosing protocol that makes K2 most effective.
FAQ
Should I take vitamin K2 with vitamin D3?
Yes — this combination is strongly recommended and mechanistically synergistic. Vitamin D3 increases intestinal calcium absorption (by up to 40%) and upregulates the genes encoding osteocalcin and MGP — but these proteins are only functional when carboxylated by vitamin K2. Taking D3 without K2 increases circulating calcium without ensuring it’s properly directed to bone, which may theoretically increase soft-tissue and arterial calcification risk. The combination ensures that the additional calcium absorbed under D3’s influence is properly utilized. Standard combined dose: 2,000–5,000 IU D3 + 90–180 mcg MK-7, taken together with a fat-containing meal daily.
Can vitamin K2 reverse arterial calcification?
The evidence suggests K2 can slow and potentially stabilize existing arterial calcification rather than reversing established deposits. The VitaK-CAC trial showed that 180 mcg/day MK-7 for 2 years stabilized coronary artery calcium scores in patients who already had significant calcification, while placebo subjects continued to accumulate calcium. “Reversal” of established calcification is not supported by current evidence — calcium deposits in arteries are difficult to dissolve without targeted interventions. The prevention benefit is far clearer: population studies consistently show that adequate K2 intake is associated with dramatically lower rates of arterial calcification development. Start K2 supplementation early, before calcification is established.
What is the difference between K2 MK-4 and MK-7 for supplements?
For practical supplementation purposes, MK-7 is superior for once-daily dosing due to its 72-hour half-life vs. MK-4’s 1–2 hours. MK-7 at 180 mcg/day produces sustained carboxylation of osteocalcin and MGP throughout the day; MK-4 at equivalent microgram doses produces only transient activation. The clinical doses of MK-4 that show bone benefits (45 mg/day in Japanese trials) are 100–250x higher than typical MK-4 supplement doses (100–500 mcg/day). Unless you are using MK-4 at pharmacological doses (45 mg/day) under physician supervision, MK-7 is the evidence-based choice for supplementation. Some advanced formulas combine both forms — providing MK-4’s rapid initial peak with MK-7’s sustained baseline — but the additional benefit over MK-7 alone is unproven.
How long does it take for vitamin K2 to show benefits?
Carboxylation of osteocalcin and MGP — the immediate biochemical effect — begins improving within 4 weeks of adequate MK-7 supplementation at 180 mcg/day (confirmed by plasma dp-ucMGP measurements). Measurable improvements in bone mineral density typically require 12–24 months of consistent supplementation, consistent with the slow rate of bone remodeling (the entire skeleton is replaced over approximately 10 years). Cardiovascular calcification stabilization, as shown in the VitaK-CAC trial, became apparent at the 2-year assessment point. Patience is required — K2 is a long-term structural intervention, not an acute-effect supplement. Consistent daily dosing with a fat-containing meal is more important than any other variable in determining efficacy.
Level up your recovery
Supplements work best alongside the right recovery tools. Explore our gear guides: